Cancer Vaccine Partnering Agreements -





Published: May 2014 | Pages: 231 | Version: 5

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

 

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 200 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cancer vaccine partnering.

                    

Chapter 3 provides a review of the leading cancer vaccine deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

 

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2009. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

 

Report scope 

 

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

 

Cancer Vaccine Partnering Agreements includes:

 

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2009
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 200 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2009
  • Includes adjuvant and drug delivery deals and alliances since 2009

 

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Chapter 1 – Introduction 

Chapter 2 – Trends in cancer vaccine dealmaking 

2.1. Introduction

2.2. Cancer vaccine partnering over the years

2.3. Big pharma cancer vaccine dealmaking activity

2.3. Big biotech cancer vaccine dealmaking activity

2.4. Most active in cancer vaccine partnering

2.5. Cancer vaccine partnering by deal type

2.6. Cancer vaccine partnering by stage of development

2.7. Cancer vaccine partnering by cancer indication

2.8. Disclosed deal terms for cancer vaccine partnering

2.8.1 Cancer vaccine partnering headline values

2.8.2 Cancer vaccine deal upfront payments

2.8.3 Cancer vaccine deal milestone payments

2.8.4 Cancer vaccine royalty rates

2.9. The anatomy of cancer vaccine partnering

2.9. The anatomy of a cancer vaccine deal

2.9. a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012

2.9. b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007

Chapter 3 – Leading cancer vaccine deals 

3.1. Introduction

3.2. Top cancer vaccine deals by value

Chapter 4 – Cancer vaccine dealmaking directory 

4.1. Introduction

4.2. Company A-Z

A*STAR Bioprocessing Technology Institute

Adamis Pharmaceuticals

Adjuvantix

AdnaGen

Aduro BioTech

Advaxis

Affitech

Agenus Bio

Agilent Technologies

Aldevron

Alexis Biotech

Alnylam Pharmaceuticals

AnGes MG

Antigen Express

Antigenics

Argos Therapeutics

Ariad Pharmaceuticals

Asterias Biotherapeutics

Astrimmune

Averion

Bavarian Nordic

Bayer Innovation

Baylor College

Baylor College of Medicine

Baylor Research Institute

Beijing Genomics Institute (BGI)

Bellicum Pharmaceuticals

Beth Israel Deaconess Medical Center

BinnoPharm

Bio-Matrix Scientific

BioAlliance Pharma

BioSante Pharmaceuticals

BioTime

BioVest

BioWa

Bristol-Myers Squibb

Broadvector

Brown University

Cadila Pharmaceuticals

Cancer Prevention and Research Institute of Texas

Cancer Research Institute

Cancer Research Technology

Cancer Research UK

Cancer Research Wales

Cardiff University

Catherex

Cedars-Sinai Medical Center

Champions Oncology

ChemRar High-Tech Center

City of Hope

Cleveland BioLabs

Clinipace Worldwide

Cobra Biologics

Colby Pharmaceuticals

CSIRO

CSL

CureLab Oncology

CureVac

Daiichi Sankyo

Dalton Pharma Services

Dana-Farber Cancer Institute

DCPrime

Delta-Vir

Dendreon

Department of Defense

Diosynth

Dynavax Technologies

Encorium Group

Entest BioMedical

European Union

Federal Ministry of Education and Research (BMBF)

Formatech

Forska and Vax

Fraunhofer Institute for Cell Therapy and Immunology

Fred Hutchinson Cancer Research Center

G-Con

Galena Biopharma

Genentech

Generex Biotechnology

Genetic Immunity

GenoLac

Genomic Expression

German Cancer Research Center

GlaxoSmithKline

Gradalis

Gynecologic Oncology Group

Heat Biologics

HemaCare

HemispheRx Biopharma

IBio

Ichor Medical Systems

Immatics Biotechnologies

Immune Design

ImmuneRegen BioSciences

Immunicum

ImmunoCellular Therapeutics

Immunomedics

Immunotope

Immunovaccine

ImmunoVaccine Technologies

Immunovo

Inovio Pharmaceuticals

InteRNA Technologies

IRX Therapeutics

ISSI-Strategy

Jaiva Technologies

Janssen Pharmaceuticals

Jantibody Therapeutics

Japan Vaccine

Jennerex

John Hopkins University School of Medicines

Johns Hopkins University

JSC Binnopharm

Juvaris BioTherapeutics

KAEL-GemVax

KellBenx

Kirin Pharma

Kyowa Hakko Kirin

Lipoxen

London Genetics

Ludwig Institute for Cancer Research

MabVax Therapeutics

Mary Crowley Cancer Research Center

Mayo Clinic

MD Anderson Cancer Center

Medarex

MediGene

MedImmune

Memorial Sloan Kettering Cancer Center

Merck and Co

Merck KGaA

Merck Serono

Merix Bioscience

Methodist Hospital Research Institute

Ministry of Industry and Trade of the Russian Federation

MorphoSys

Mount Sinai School of Medicine

Nanobiotix

National Cancer Institute

National Cancer Research Center

National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Research Council Canada

NeoStem

NewVac

Northwest Biotherapeutics

Norwegian Research Council

Nottingham City Council

Novartis

Novavax

Numoda

NYU Langone Medical Center

Ohio State University

Omnimmune

OncoPep

OncoSec Medical

Oncotherapy Science

Oncothyreon

Oncovir

Ono Pharmaceutical

Opsona Therapeutics

Oxford BioMedica

Oxford Immunotec

Panacela Labs

Pepscan Therapeutics

Pfenex

Pfizer

Pharmsynthez

Pique Therapeutics

Pro-Cure Therapeutics

Progenitor Cell Therapy

Prostate Cancer Foundation (PCF)

PsiOxus Therapeutics

Qiagen

Radboud University Nijmegen Medical Centre

Radient Pharmaceuticals

Regen BioPharma

Roche

RXi Pharmaceuticals

Scancell

SOTIO

Stellar Biotechnologies

Stellar Pharmaceuticals

Stemline Therapeutics

Symphony Dynamo

TapImmune

Tasly Pharmaceuticals

Technomark Life Sciences

Teva Pharmaceutical Industries

The Regents of the University of California

Therinject

ToleRx

Torrey Pines Institute for Molecular Studies

Transgene

UK Government

University of Connecticut

University of Copenhagen

University of Miami

University of Pennsylvania

University of Pennsylvania School of Veterinary Medicine

University of Pittsburgh

University of Queensland

University of Rouen

University of Western Ontario

Vaccibody

Vaccinogen

Vaxil BioTherapeutics

Vaximm

Vinnova

ViroMed

Vivalis

VLST Corporation

VU University Amsterdam

Wistar Institute

Xencor

4.3. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

4.4. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Option

Research

Sub-license

Supply

Technology transfer

Termination

Warranty

4.5. By oncology therapy area

Oncology

4.6. Cancer deals by related technology

Vaccines

Adjuvants

Chapter 5 –Partnering resource center 

5.1. Online partnering

5.2. Partnering events

5.3. Further reading on dealmaking

 

Appendices 

Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Technology Reports

Order Form – Reports

  

Table of figures 

 

Figure 1: Cancer vaccine partnering since 2009

Figure 2: Big pharma – top 50 – cancer vaccine deals 2009 to 2014

Figure 3: Big pharma cancer vaccine deal frequency – 2009 to 2014

Figure 4: Big biotech – top 50 – cancer vaccine deals 2009 to 2014

Figure 5: Big biotech cancer vaccine deal frequency – 2009 to 2014

Figure 6: Active cancer vaccine dealmaking activity– 2009 to 2014

Figure 7: Cancer vaccine partnering by deal type since 2009

Figure 8: Cancer vaccine partnering by stage of development since 2009

Figure 9: Vaccine partnering by oncology target since 2009

Figure 10: Cancer vaccine deals with a headline value – by stage of development

Figure 11: Cancer vaccine deal headline value distribution, US$million – discovery stage

Figure 12: Cancer vaccine deal headline value distribution, US$million – preclinical stage

Figure 13: Cancer vaccine deal headline value distribution, US$million – phase I stage

Figure 14: Cancer vaccine deal headline value distribution, US$million – phase II stage

Figure 15: Cancer vaccine deal headline value distribution, US$million – phase III stage

Figure 16: Cancer vaccine deal headline value distribution, US$million – regulatory stage

Figure 17: Cancer vaccine deal headline value distribution, US$million – marketed stage

Figure 18: Cancer vaccine deal headline value – median value by stage of development

Figure 19: Cancer vaccine deals with upfront payment values – by stage of development

Figure 20: Cancer vaccine deal upfront value distribution, US$million – discovery stage

Figure 21: Cancer vaccine deal upfront value distribution, US$million – preclinical stage

Figure 22: Cancer vaccine deal upfront value distribution, US$million – phase I stage

Figure 23: Cancer vaccine deal upfront value distribution, US$million – phase II stage

Figure 24: Cancer vaccine deal upfront value distribution, US$million – phase III stage

Figure 25: Cancer vaccine deal upfront value distribution, US$million – regulatory stage

Figure 26: Cancer vaccine deal upfront value distribution, US$million – marketed stage

Figure 27: Cancer vaccine deal upfront payment value – median value by stage of development

Figure 28: Cancer vaccine deals with milestone payment – by stage of development

Figure 29: Cancer vaccine deal milestone value distribution, US$million – discovery stage

Figure 30: Cancer vaccine deal milestone value distribution, US$million – preclinical stage

Figure 31: Cancer vaccine deal milestone value distribution, US$million – phase I stage

Figure 32: Cancer vaccine deal milestone value distribution, US$million – phase II stage

Figure 33: Cancer vaccine deal milestone value distribution, US$million – phase III stage

Figure 34: Cancer vaccine deal milestone value distribution, US$million – regulatory stage

Figure 35: Cancer vaccine deal milestone value distribution, US$million – marketed stage

Figure 36: Cancer vaccine deals with royalty rates-by stage of development

Figure 37: Cancer vaccine deal royalty rate value distribution, US$million – discovery stage

Figure 38: Cancer vaccine deal royalty rate value distribution, US$million – preclinical stage

Figure 39: Cancer vaccine deal royalty rate value distribution, US$million – phase I stage

Figure 40: Cancer vaccine deal royalty rate value distribution, US$million – phase II stage

Figure 41: Cancer vaccine deal royalty rate value distribution, US$million – phase III stage

Figure 42: Cancer vaccine deal royalty rate value distribution, US$million – regulatory stage

Figure 43: Cancer vaccine deal royalty rate value distribution, US$million – marketed stage

Figure 44: Cancer vaccine deal royalty rate payment value – median value by stage of development

Figure 45: Components of the typical cancer vaccine deal structure

Figure 46: Top cancer vaccine deals by value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events

Figure 49: Deal type definitions